Dimensional Fund Advisors LP Sells 60,918 Shares of United Therapeutics Corporation $UTHR

Dimensional Fund Advisors LP reduced its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 10.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 512,816 shares of the biotechnology company’s stock after selling 60,918 shares during the period. Dimensional Fund Advisors LP’s holdings in United Therapeutics were worth $214,995,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Clearstead Advisors LLC boosted its holdings in United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 23 shares during the last quarter. Bessemer Group Inc. grew its position in United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after purchasing an additional 28 shares in the last quarter. Archer Investment Corp increased its stake in United Therapeutics by 9.5% in the 3rd quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 31 shares during the last quarter. F m Investments LLC increased its stake in United Therapeutics by 1.3% in the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after buying an additional 33 shares during the last quarter. Finally, WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

Shares of UTHR opened at $478.16 on Friday. The company has a market cap of $20.96 billion, a PE ratio of 17.14, a price-to-earnings-growth ratio of 1.72 and a beta of 0.84. The firm has a 50-day moving average of $482.51 and a 200-day moving average of $453.25. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $537.19.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same period in the prior year, the firm earned $6.19 EPS. United Therapeutics’s quarterly revenue was up 7.4% compared to the same quarter last year. Analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating — a notable analyst endorsement implying material upside that could attract buyers. Read More.
• Neutral Sentiment: Multiple sell?side firms have recently increased targets and reiterated Buy/outperform views (Oppenheimer, HC Wainwright, TD Cowen); consensus remains a “Moderate Buy” with a mid?range price target, supporting a constructive medium?term thesis. Read More.
• Negative Sentiment: A wave of insider selling this week is pressuring sentiment: CEO Martine Rothblatt sold 9,500 shares (~$4.65M), and several directors/executives (Ray Kurzweil, Paul Mahon, Tommy G. Thompson and others) also sold blocks at roughly $483–$490 per share. These large, concentrated disposals can prompt near?term weakness even if insiders retain stakes. Read More. Read More.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 21,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $478.60, for a total value of $10,050,600.00. Following the sale, the chief financial officer owned 8,142 shares in the company, valued at $3,896,761.20. This represents a 72.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $496.30, for a total value of $11,166,750.00. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 377,184 shares of company stock worth $183,015,947. Company insiders own 10.30% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent research reports. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. TD Cowen increased their price target on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Royal Bank Of Canada raised their price target on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Finally, Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $539.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.